Identification of chondroitin polymerizing factor (CHPF) as tumor promotor in cholangiocarcinoma through regulating cell proliferation, cell apoptosis and cell migration

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34.
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.
   PubMed Web of Science ®Google Scholar
• Razumilava N, Gores GJ. Cholangiocarcinoma. Lancet. 2014;383(9935):2168–2179.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Khan SA, Hallemeier CL, et al. Cholangiocarcinoma - evolving concepts and therapeutic strategies. Nat Rev Clin Oncol. 2017;15(2):95–111.
   PubMed Web of Science ®Google Scholar
• Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19(1):2.
   PubMedGoogle Scholar
• Esnaola NF, Meyer JE, Karachristos A, et al. Evaluation and management of intrahepatic and extrahepatic cholangiocarcinoma. Cancer-Am Cancer Soc. 2016;122:1349–1369.
   PubMed Web of Science ®Google Scholar
• Rizvi S, Gores GJ. Pathogenesis, diagnosis, and management of Cholangiocarcinoma. Gastroenterology. 2013;145(6):1215–1229.
   PubMed Web of Science ®Google Scholar
• Moeini A, Sia D, Bardeesy N, et al. Molecular pathogenesis and targeted therapies for intrahepatic Cholangiocarcinoma. Clin Cancer Res. 2016;22(2):291.
   PubMed Web of Science ®Google Scholar
• Volpi N, Maccari F, Mantovani V. Chondroitin Sulfate and Glucosamine as disease modifying anti- osteoarthritis drugs (DMOADs). Curr Med Chem. 2016;23(11):1139–1151.
   PubMed Web of Science ®Google Scholar
• Mikami T, Kitagawa H. Biosynthesis and function of chondroitin sulfate. Biochim Biophys Acta Gen Subj. 2013;1830(10):4719–4733.
   Web of Science ®Google Scholar
• Bishnoi M, Jain A, Hurkat P, et al. Chondroitin sulphate: a focus on osteoarthritis. Glycoconjugate J. 2016;33(5):1–13.
   PubMed Web of Science ®Google Scholar
• Maksimenko AV, Golubykh VL, Tischenko EG. Catalase and chondroitin sulfate derivatives against thrombotic effect induced by reactive oxygen species in a rat artery. Metab Eng. 2003;5(3):177–182.
   PubMed Web of Science ®Google Scholar
• Rolls A, Shechter R, London A, et al. Two faces of chondroitin sulfate proteoglycan in spinal cord repair: a role in microglia/macrophage activation. PLoS Med. 2008;5(8):e171.
   PubMed Web of Science ®Google Scholar
• Nadanaka S, Kinouchi H, Kitagawa H. Chondroitin sulfates-mediated N-cadherin/β-catenin signaling is associated with basal-like breast cancer cell invasion. J Biol Chem. 2017;293(2):444–465.
   PubMed Web of Science ®Google Scholar
• Pantazaka E, Papadimitriou E. Chondroitin sulfate-cell membrane effectors as regulators of growth factor-mediated vascular and cancer cell migration. Biochim Biophys Acta. 2014;1840(8):2643–2650.
   PubMed Web of Science ®Google Scholar
• Asimakopoulou AP, Theocharis AD, Tzanakakis GN, et al. The biological role of chondroitin sulfate in cancer and chondroitin-based anticancer agents. In Vivo. 2008;22(3):385–389.
   PubMed Web of Science ®Google Scholar
• Kitagawa H, Izumikawa T, Uyama T, et al. Molecular cloning of a chondroitin polymerizing factor that cooperates with chondroitin synthase for chondroitin polymerization. J Biol Chem. 2003;278(26):23666–23671.
   PubMed Web of Science ®Google Scholar
• Kalathas D, Triantaphyllidou IE, Mastronikolis NS, et al. The chondroitin/dermatan sulfate synthesizing and modifying enzymes in laryngeal cancer: expressional and epigenetic studies. Head Neck Oncol. 2010;2(1):27.
   PubMedGoogle Scholar
• Hwang S, Mahadevan S, Qadir F, et al. Identification of FOXM1-induced epigenetic markers for head and neck squamous cell carcinomas. Cancer-Am Cancer Soc. 2013;119:4249–4258.
   PubMed Web of Science ®Google Scholar
• Cao C, Liu Y, Wang Q, et al. Expression of CHPF modulates cell proliferation and invasion in lung cancer. Braz J Med Biol Res = Rev Bras Pesqui Med Biol. 2020;53(5):e9021.
   PubMed Web of Science ®Google Scholar
• Xu Q, Lin W, Tao C, et al. Chondroitin polymerizing factor (CHPF) contributes to malignant proliferation and migration of hepatocellular carcinoma cells. Biochem Cell Biol. 2020;98(3):362–369.
   PubMedGoogle Scholar
• Sun W, Zhao F, Xu Y, et al. Chondroitin polymerizing factor (CHPF) promotes development of malignant melanoma through regulation of CDK1. Cell Death Dis. 2020;11(7):496.
   PubMed Web of Science ®Google Scholar
• Izumikawa T, Koike T, Shiozawa S, et al. Identification of chondroitin sulfate glucuronyltransferase as chondroitin synthase-3 involved in chondroitin polymerization. J Biol Chem. 2008;283(17):11396–11406.
   PubMed Web of Science ®Google Scholar
• Takeda A, Okada S, Funakoshi K. Chondroitin sulfates do not impede axonal regeneration in goldfish spinal cord. Brain Res. 2017;16:23–29.
   Google Scholar
• Zhao R, Ackers-Johnson M, Stenzig J, et al. Targeting chondroitin sulfate glycosaminoglycans to treat cardiac fibrosis in pathological remodeling. Circulation. 2018;137(23):2497–2513.
   PubMed Web of Science ®Google Scholar
• Tsidulko AY, Kazanskaya GM, Volkov AM, et al. Chondroitin sulfate content and decorin expression in glioblastoma are associated with proliferative activity of glioma cells and disease prognosis. Cell Tissue Res. 2020;379(1):147–155.
   PubMed Web of Science ®Google Scholar
• Chen X, Yin T, Zhang B, et al. Inhibitory effects of brusatol delivered using glycosaminoglycan‑placental chondroitin sulfate A‑modified nanoparticles on the proliferation, migration and invasion of cancer cells. Int J Mol Med. 2020;46(2):817–827.
   PubMed Web of Science ®Google Scholar
• Hou X, Zhang T, Da Z, et al. CHPF promotes lung adenocarcinoma proliferation and anti-apoptosis via the MAPK pathway. Pathol Res Pract. 2019;215(5):988–994.
   PubMed Web of Science ®Google Scholar
• Hou X, Baloch Z, Zheng Z, et al. Knockdown of CHPF suppresses cell progression of non-small-cell lung cancer. Cancer Manag Res. 2019;11:3275–3283.
   PubMed Web of Science ®Google Scholar
• Ye W, Zhu J, He D, et al. Increased CDKL3 expression predicts poor prognosis and enhances malignant phenotypes in esophageal squamous cell carcinoma. J Cell Biochem. 2019;120(5):7174–7184.
   Web of Science ®Google Scholar
• Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11(1):28–39.
   PubMed Web of Science ®Google Scholar
• Diepenbruck M, Christofori G. Epithelial-mesenchymal transition (EMT) and metastasis: yes, no, maybe? Curr Opin Cell Biol. 2016;43:7–13.
   PubMed Web of Science ®Google Scholar
• Liao TT, Yang MH. Revisiting epithelial-mesenchymal transition in cancer metastasis: the connection between epithelial plasticity and stemness. Mol Oncol. 2017;11(7):792–804.
   PubMed Web of Science ®Google Scholar
• Marcucci F. G Stassi and RD Maria, Epithelial|[ndash]|mesenchymal transition: a new target in anticancer drug discovery. Nat Rev Drug Discov. 2016;15(5):311–325.
   PubMed Web of Science ®Google Scholar
• Samy L. X Jian and D Rik, Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Bio. 2014;15:178–196.
   PubMed Web of Science ®Google Scholar
• Loh C, Tang W, Sethi S, et al. The E-Cadherin and N-Cadherin Switch in Epithelial-to-Mesenchymal Transition: signaling, Therapeutic Implications, and Challenges. Cells-Basel. 2019;8(10):1118.
   PubMed Web of Science ®Google Scholar
• Xu X, Gu J, Ding X, et al., LINC00978 promotes the progression of hepatocellular carcinoma by regulating EZH2-mediated silencing of p21 and E-cadherin expression. Cell Death Dis. 2019;10(10):752.
   PubMed Web of Science ®Google Scholar
• Zhu Z, Rong Z, Luo Z, et al. Circular RNA circNHSL1 promotes gastric cancer progression through the miR-1306-3p/SIX1/vimentin axis. Mol Cancer. 2019;18(1):126.
   PubMed Web of Science ®Google Scholar